C. R. Bard
C. R. Bard, Inc. (Template:Nyse) is one of the large S&P 500 companies of the United States, a surgical specialties and hospital medical device manufacturer in Murray Hill, New Jersey. It is named after its founder, who sold the company within only a few years of its founding. In later decades it grew to its current size largely through many small acquisitions.
In 1974 it went international, with plants in South America and Japan.
Bard peformed well through the long bear market of the 1970s. Its stock rose, from the low early in that decade, to up by seven-fold times by its 1983 peak. It split three-for-two in 1982.
By 1986, Bard had become listed in the S&P 500 among the largest 500 publicly-traded companies in the United States. Annual earnings by 1986 were over US$40 million. In 1986 the stock split again, two-for-one.
By the late 1980s, the stock had again split two-for-one.
In 1990, Bard formed the divisions Bard Electrophysiology, Bard Interventional Products, Bard Peripheral Technologies, and Specialty Access Products Business Group.
In 1994, net sales revenue reached over the US$1 billion milestone for the first time.
In 1996 Bard's new division Bard Medical Products was formed from the groups Davol, Bard Urological and Bard Patient Care.
In 1998 Bard did some significant divestments of businesses, as it sold the Coronary Cath Lab division to Arterial Vascular Engineering, and sold the Diagnostic Sciences division to Polymedco, and sold Global Intra-Aortic Balloon Products division to Arrow International, Inc.
- 1966, Bard acquired USCI, with which it had an association dating back to 1941.
- 1975, Bard acquired William Harvey Research Corp.
- 1980, Bard acquired Davol Inc.
- 1986, Bard acquired American Endoscopy, Inc.
- 1989, Bard acquired Catheter Technology Corporation, which in 1991 became Bard Access Systems, Inc.
- 1998, Dymax of Pittsburgh, Pennsylvania
- 2005, GENYX Medical, Inc. assets
- About Bard, C. R. Bard, History
- Standard & Poor's Stock Guide, various issues